Ovid Therapeutics: Analyzing Valuation Amidst a 700% Stock Surge
Ovid Therapeutics has experienced a staggering 700% increase in its stock price. However, risk-adjusted valuation suggests that the stock may still be undervalued.
Editorial Staff 6 days ago